Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE)

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study

(2017) William Stohl et al.   Arthritis & Rheumatology

Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review

(2016) C E Henegar et al.   LUPUS

Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus

(2016) Luca Iaccarino et al.   ARTHRITIS CARE & RESEARCH

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus

(2015) Tobias Alexander et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

(2015) J T Merrill et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

(2015) D A Isenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices

(2015) J. S. Hui-Yuen et al.   JOURNAL OF RHEUMATOLOGY

Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab

(2015) D A Roth et al.   LUPUS

Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials

(2015) William Stohl et al.   ARTHRITIS RESEARCH & THERAPY

Differential Development of Systemic Lupus Erythematosus in NZM 2328 Mice Deficient in Discrete Pairs of BAFF Receptors

(2015) Chaim O. Jacob et al.   Arthritis & Rheumatology

BAFF Regulates Follicular Helper T Cells and Affects Their Accumulation and Interferon-γ Production in Autoimmunity

(2015) Christine M. Coquery et al.   Arthritis & Rheumatology

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study

(2014) R A Furie et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)

(2014) David Isenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Cutting Edge: The Dependence of Plasma Cells and Independence of Memory B Cells on BAFF and APRIL

(2014) M. J. Benson et al.   JOURNAL OF IMMUNOLOGY

A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab

(2014) CA Fredericks et al.   LUPUS

Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials

(2013) Michelle A. Petri et al.   ARTHRITIS AND RHEUMATISM

Development of Systemic Lupus Erythematosus in NZM 2328 Mice in the Absence of any Single BAFF Receptor

(2013) Chaim O. Jacob et al.   ARTHRITIS AND RHEUMATISM

Genetic susceptibility to SLE: Recent progress from GWAS

(2013) Yong Cui et al.   JOURNAL OF AUTOIMMUNITY

CVID-associated TACI mutations affect autoreactive B cell selection and activation

(2013) Neil Romberg et al.   JOURNAL OF CLINICAL INVESTIGATION

Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus

(2013) E. M. Ginzler et al.   JOURNAL OF RHEUMATOLOGY

Elevated B lymphocyte stimulator levels are associated with increased damage in an Irish systemic lupus erythematosus cohort

(2013) E. M. McCarthy et al.   RHEUMATOLOGY

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

(2012) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

(2012) Susan Manzi et al.   ANNALS OF THE RHEUMATIC DISEASES

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

(2012) William Stohl et al.   ARTHRITIS AND RHEUMATISM

Effect of Belimumab on Vaccine Antigen Antibodies to Influenza, Pneumococcal, and Tetanus Vaccines in Patients with Systemic Lupus Erythematosus in the BLISS-76 Trial

(2012) W. WINN CHATHAM et al.   JOURNAL OF RHEUMATOLOGY

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus

(2012) DJ Wallace et al.   LUPUS

Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE

(2012) MA Dooley et al.   LUPUS

The discovery and development of belimumab: the anti-BLyS–lupus connection

(2012) William Stohl et al.   NATURE BIOTECHNOLOGY

Selective APRIL Blockade Delays Systemic Lupus Erythematosus in Mouse

(2012) Bertrand Huard et al.   PLoS One

Deficiency in TNFRSF13B (TACI) expands T-follicular helper and germinal center B cells via increased ICOS-ligand expression but impairs plasma cell survival

(2012) X. Ou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial

(2012) Ellen M Ginzler et al.   ARTHRITIS RESEARCH & THERAPY

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice

(2011) Chaim O. Jacob et al.   ARTHRITIS AND RHEUMATISM

Treatment for Lupus, First in 50 Years, Offers Modest Benefits, Hope to Patients

(2011) Mike Mitka   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Protective antiviral antibody responses in a mouse model of influenza virus infection require TACI

(2011) Amaya I. Wolf et al.   JOURNAL OF CLINICAL INVESTIGATION

B Cell Maturation Antigen Deficiency Exacerbates Lymphoproliferation and Autoimmunity in Murine Lupus

(2011) C. Jiang et al.   JOURNAL OF IMMUNOLOGY

B Cell and BAFF Dependence of IFN- -Exaggerated Disease in Systemic Lupus Erythematosus-Prone NZM 2328 Mice

(2011) N. Jacob et al.   JOURNAL OF IMMUNOLOGY

Soluble BAFF Levels Inversely Correlate with Peripheral B Cell Numbers and the Expression of BAFF Receptors

(2011) M. Kreuzaler et al.   JOURNAL OF IMMUNOLOGY

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Increased levels of BAFF in patients with systemic lupus erythematosus are associated with acute-phase reactants, independent of BAFF genetics: a case–control study

(2011) Gro Ø. Eilertsen et al.   RHEUMATOLOGY

Raised serum level of APRIL in patients with systemic lupus erythematosus: Correlations with disease activity indices

(2010) M. Hegazy et al.   CLINICAL IMMUNOLOGY

Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses

(2010) Claudia Bossen et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B cell maturation antigen-immunoglobulin

(2010) Stacey R Dillon et al.   ARTHRITIS RESEARCH & THERAPY

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

(2009) Daniel J. Wallace et al.   ARTHRITIS AND RHEUMATISM

Novel evidence-based systemic lupus erythematosus responder index

(2009) Richard A. Furie et al.   ARTHRITIS AND RHEUMATISM

An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus

(2009) C Pena-Rossi et al.   LUPUS

Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus

(2008) J Morel et al.   ANNALS OF THE RHEUMATIC DISEASES

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

(2008) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM

APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells

(2008) E. Belnoue et al.   BLOOD

BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact

(2008) J. L. Scholz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

(2008) Richard Furie et al.   ARTHRITIS RESEARCH & THERAPY